Press release
Hypertension Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)
Key Takeaways from Hypertension Pipeline Report
*
DelveInsight's Hypertension pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Hypertension treatment.
*
The leading companies working in the Hypertension Market include Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics Inc., Aadi Bioscience Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma LLC, PolyActiva Pty Ltd, pH Pharma, Nicox Ophthalmics, Inc., Ocular Therapeutix, Inc., Santen SAS, Whitecap Biosciences LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co., Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IlDong Pharmaceutical Co Ltd, Qlaris Bio Inc., and others.
*
Promising Hypertension Pipeline Therapies in the various stages of development include Irbesartan/HCTZ, Riociguat (Adempas, BAY63-2521), Bisoprolol, Atenolol, Tadalafil, LCI699, Eplerenone, and others.
*
April 2024:- Laboratorios Silanes SA De CV- Phase IIIb, randomized, double-blind, prospective, multicenter study to evaluate the efficacy and safety of the fixed-dose combination of losartan / chlorthalidone compared with losartan / hydrochlorothiazide in the treatment of patients with essential arterial hypertension.
*
April 2024:- Servier Russia- DescripTion of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/atoRvastatin/Perindopril sinGle Pill Combination trEatmenT in Patients With Arterial Hypertension and Dyslipidemia in the Daily Clinical Practice. (TARGET). This is a multi-centre, observational, ambispective study, which will retrospectively and prospectively collect clinical and socio-demographic data from medical records of patients with HTN and dyslipidemia initiated with SPC of amlodipine/atorvastatin/perindopril in real clinical settings.
*
April 2024:- Cereno Scientific AB- A Phase 2, Prospective, Randomized, Open-label, Blinded Endpoint, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of 3 Doses of CS1 in Subjects With Pulmonary Arterial Hypertension. This is a Phase 2, parallel group study to evaluate the safety, tolerability, PK, and exploratory efficacy of 3 doses of CS1 in the treatment of PAH using the CardioMEMS HF System to obtain repeated measurements of PAP and other hemodynamic parameters.
Request a sample and discover the recent advances in Hypertension Treatment Drugs @ Hypertension Pipeline Report [https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
In the Hypertension pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertension collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Hypertension Overview
Hypertension is the most common primary diagnosis in the United States. It affects approximately 86 million adults ( greater than or equal to 20 years) in the United States and is a major risk factor for stroke, myocardial infarction, vascular disease, and chronic kidney disease. Hypertension is defined as a systolic blood pressure (SBP) of 140 mm Hg or more, or a diastolic blood pressure (DBP) of 90 mm Hg or more, or taking antihypertensive medication.
Find out more about Hypertension Therapeutics Assessment @ Hypertension Preclinical and Discovery Stage Products [https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hypertension Emerging Drugs Profile
*
Firibastat: Quantum Genomics
*
Baxdrostat (CIN-107): CinCor Pharma
*
MLS-101: Mineralys Therapeutics
*
Zilebesiran (ALN-AGT): Alnylam Therapeutics
*
IONIS-AGT-LRx: Ionis Pharmaceuticals
Hypertension Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the Hypertension therapies. The Hypertension companies which have their Hypertension drug candidates in the most advanced stage, i.e. phase III include, Reata Pharmaceuticals.
DelveInsight's Hypertension pipeline report covers around 100+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Inhalation
*
Inhalation/Intravenous/Oral
*
Intranasal
*
Intravenous
*
Intravenous/ Subcutaneous
*
NA
*
Oral
*
Oral/intranasal/subcutaneous
*
Parenteral
*
Subcutaneous
Hypertension Pipeline Products have been categorized under various Molecule types such as
*
Antibody
*
Antisense oligonucleotides
*
Immunotherapy
*
Monoclonal antibody
*
Peptides
*
Protein
*
Recombinant protein
*
Small molecule
*
Stem Cell
*
Vaccine
Learn more about the emerging Hypertension Pipeline Therapies @ Hypertension Clinical Trials Assessment [https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Hypertension Pipeline Report
*
Coverage- Global
*
Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
*
Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
*
Hypertension Companies- Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics Inc., Aadi Bioscience Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma LLC, PolyActiva Pty Ltd, pH Pharma, Nicox Ophthalmics, Inc., Ocular Therapeutix, Inc., Santen SAS, Whitecap Biosciences LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co., Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IlDong Pharmaceutical Co Ltd, Qlaris Bio Inc., and others.
*
Hypertension Pipeline Therapies- Irbesartan/HCTZ, Riociguat (Adempas, BAY63-2521), Bisoprolol, Atenolol, Tadalafil, LCI699, Eplerenone, and others.
Dive deep into rich insights for new drugs for Hypertension Treatment, Visit @ Hypertension Market Drivers and Barriers, and Future Perspective [https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
*
Introduction
*
Executive Summary
*
Hypertension: Overview
*
Pipeline Therapeutics
*
Therapeutic Assessment
*
Hypertension - DelveInsight's Analytical Perspective
*
Late Stage Products (Phase III)
*
Firibastat: Quantum Genomics
*
Drug profiles in the detailed report.....
*
Mid Stage Products (Phase II)
*
Baxdrostat (CIN-107): CinCor Pharma
*
Drug profiles in the detailed report.....
*
Early Stage Products (Phase I)
*
ID-140009: IlDong Pharmaceutical
*
Drug profiles in the detailed report.....
*
Preclinical and Discovery Stage Products
*
CKD 331: Chong Kun Dang
*
Drug profiles in the detailed report.....
*
Inactive Products
*
Hypertension Key Companies
*
Hypertension Key Products
*
Hypertension- Unmet Needs
*
Hypertension- Market Drivers and Barriers
*
Hypertension- Future Perspectives and Conclusion
*
Hypertension Analyst Views
*
Hypertension Key Companies
*
Appendix
For further information on the Hypertension Pipeline therapeutics, reach out to Hypertension Unmet Needs and Analyst Views [https://www.delveinsight.com/sample-request/hypertension-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypertension-pipeline-outlook-fda-approvals-clinical-trials-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypertension Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated) here
News-ID: 3489683 • Views: …
More Releases from ABNewswire
Living Water Resorts Joins GNEX 2026 as Gold Sponsor
Waterfront Resort Leader Supports Industry-Shaping Event in Nashville
Orlando, Fla. - February 17, 2026 - The Perspective Group and GNEX (Growth Networking EXperience) Conference today announced that Living Water Resorts, the only resort destination located on the shores of Georgian Bay in the heart of Collingwood, Ontario, will join GNEX 2026 as a Gold Sponsor. The event will take place March 18-20, 2026, at the JW Marriott in downtown Nashville, Tennessee.
As…
MAHA Uncensored: As RFK Jr.'s "Eat Real Food" Movement Captures National Attenti …
Salt Lake City, Utah - As Robert F. Kennedy Jr.'s Make America Healthy Again (MAHA) movement continues to dominate national headlines - from the widely discussed "Eat Real Food" Super Bowl advocacy campaign to renewed scrutiny of ultra-processed food policy and federal regulatory oversight - a powerful new documentary is set to expand the national conversation.
MAHA Uncensored, directed by award-winning filmmaker Jeff Hays ( The Real Anthony Fauci , On…
Consumers Shifting Toward Canadian-Made Adaptogenic Sipping Chocolate Over Tradi …
A growing number of Canadians are replacing traditional powdered hot chocolate with adaptogenic sipping chocolate made from ceremonial cacao and functional superfoods.
Golden, BC - Across Canada, consumers are increasingly turning away from conventional powdered hot chocolate and toward Canadian-produced adaptogenic sipping chocolates as part of a broader interest in functional foods, as well as healthier coffee alternatives and daily rituals that support energy, focus, and rest.
Unlike traditional hot chocolate mixes,…
Uveitis Clinical Trial Pipeline Expands as 15+ Companies Advance 15+ Targeted Oc …
DelveInsight's "Uveitis - Pipeline Insight, 2026" report provides comprehensive insights about 15+ companies, including Eli Lilly and Company, Santen Inc., Clearside Biomedical, Affibody, Eyevensys, Alcon Research, Panoptes Pharma, Tarsier Pharma, Eye Pharma, Apitope Technology, Mitotech, and others, developing 15+ pipeline drugs in the Uveitis pipeline landscape.
DelveInsight's "Uveitis - Pipeline Insight, 2026" report provides comprehensive insights about 15+ companies developing 15+ pipeline drugs in the Uveitis pipeline landscape. It covers Uveitis…
More Releases for Hypertension
Hypertension Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Hypertension Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Hypertension pipeline landscape. It covers the Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hypertension pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Hypertension Pipeline Report
• DelveInsight's Hypertension…
Hypertension Drugs Market - Breaking the Pressure: Hypertension Drugs Redefining …
Newark, New Castle, USA: The "Hypertension Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Hypertension Drugs Market: https://www.growthplusreports.com/report/hypertension-drugs-market/8760
This latest report researches the industry structure, sales, revenue,…
Hypertension Management Devices Market: Rise in Prevalence of Resistant Hyperten …
Market Analysis and Insights of Hypertension Management Devices Market
Hypertension Management Devices Market to account USD 9.50 billion and growing at a CAGR of 7.27% by 2032. Although there are still numerous variations available, the major market players are currently developing and testing clinical versions of hypertension treatment devices. Due to the lack of available effective medications, these medical devices are being created with the primary goal of managing cardiovascular illnesses…
Anti-hypertension - Drug Pipeline Landscape, 2022
Hypertension also known as high blood pressure is a condition where the force of blood pushing against the arterial walls of heart is consistently higher than the normal. Hypertension can be identified as primary/essential (without a known cause such as age, genetics, sedentary lifestyle, alcohol consumption, high sodium intake etc.) and secondary (due to an underlying condition as its cause such as congenital heart defects, kidney diseases, endocrinal issues, side…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
Renal Hypertension: Diagnosis & Treatment
“Hypertension & Cardiovascular disease after Kidney Transplantation” is one of the workshops to be conducted by Dr. Hossein Tabriziani of Loma Linda University, USA under the session ‘Renal Hypertension’ at the meeting 2nd International Conference on Hypertension & Healthcare which is going to be held at Amsterdam, Netherlands during September 11-13, 2017.
High blood pressure is a leading cause of kidney disease and kidney failure ESRD (end stage renal disease). Hypertension…
